Aurobindo Pharma announced its consolidated financial results for the quarter ended September 30, 2026.

The company's revenue from operations stood at INR 10,263 crore, reporting an increase of 24 percent YoY, driven by growth across businesses, while net profit for the quarter stood at INR 1,124 crore.

US formulation revenue increased by 25 percent YoY to Rs. 4,555 crore primarily driven by successful integration, base business growth and new launches. API revenues increased 21 percent YoY to INR 1,162 crore, driven by favourable business mix and contributed 11 percent of consolidated revenue.

Commenting on the company’s performance, K Nithyananda Reddy, Vice-Chairman and Managing Director of the company, said, “We are pleased to deliver a strong performance in Q2, reflecting the strength of our business fundamentals, sustained execution and the resilience of our diversified product portfolio. Our growth is supported by healthy organic momentum across our key businesses and the successful integration of inorganic opportunities, further strengthening our capabilities and positioning us for the future. As we advance our strategic priorities, we remain focused on sustainable growth, financial discipline and creating long-term value for our stakeholders, while continuing to expand access to quality and affordable healthcare worldwide.”